Biophytis is deploying its partnership strategy in obesity

Biophytis / Key word(s): Miscellaneous Biophytis is deploying its partnership strategy in obesity 29-Apr-2024 / 14:39 CET/CEST Biophytis is deploying its partnership strategy in obesity

Paris (France) and Cambridge (Massachusetts, USA), April 29, 2024 – 07:00 am CET – Biophytis SA (Euronext Growth Paris : ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the  development of  therapeutics for age-related diseases, today announces the implementation of a dedicated strategy for partner search in obesity.

 

Biophytis is continually working on the search for partners thanks to a sound strategy and action plan, with the Company being fully committed to drive groundbreaking scientific and technological advances that have the potential to transform the lives of obese patients worldwide.

 

Biophytis’ partnering strategy is based on the search for the best partners selected through precise targeting and an in-depth analysis and understanding of the pharmaceutical landscape to select the right partners and identify mutual benefits. We are looking to licence-out BI0101 (20-hydroxyecdysones) to regional or global pharmaceutical companies that will co-develop with us the drug candidate up to marketing authorization in the treatment of obesity and other indications and have the capacity to launch and commercialize it in the main regions. BIO101 (20-hydroxyecdysone) is in clinical development (phase 2 OBA study in preparation) in obesity, in combination with GLP-1 receptor agonists (GLP1-RA).

 

Furthemore, the Company has established a refined and tailored action plan to serve these objective, which includes close collaboration with local agents to provide expertise and network and a Senior Management’s presence in the most attractive business events in pharma. For this, Biophytis will atttend the BIO US conference, the largest business development conference on the American continent to be held from June 3 to 6 in San Diego.